GE HealthCare Technologies
GEHC
80.64
-1.25
-1.53%
GE HealthCare Technologies
US · GEHC
#689 by market cap
Listed 2022
80.64
-1.25
-1.53%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q4).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 94.86%
- Institutions
- 1,488 -1
- As of
- 2026/Q4 vs. prior period
Holder types
Mutual Fund82.34%
Public Company3.43%
Hedge Fund3.16%
Government Pension Fund1.88%
Private Company1.43%
Sovereign Wealth Fund1.33%
VC/PE Fund0.43%
Family Office/Trust0.30%
Insurance Company0.23%
Individual/Insider0.22%
Other5.48%
Top holders as of 2026-09-30
Dodge & Cox
10.68% · 48.30M sh
BlackRock
8.26% · 37.34M sh
Vanguard Capital Management, LLC
7.11% · 32.14M sh
State Street Global Advisors
4.64% · 21.00M sh
Vanguard Portfolio Management, LLC
4.41% · 19.94M sh
Invesco Capital Management LLC
3.42% · 15.46M sh
Harris Associates L.P.
3.29% · 14.87M sh
Barrow, Hanley, Mewhinney & Strauss, LLC
3.05% · 13.77M sh
Hotchkis and Wiley Capital Management, LLC
2.95% · 13.34M sh
Geode Capital Management, LLC
2.86% · 12.94M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 30 buys · 17 sells
| Name | Role | Stake |
|---|---|---|
| H. Culp | Independent Chairperson | 0.11% |
| Peter Arduini | Chief Executive Officer | 0.03% |
| Frank Jimenez | General Counsel | 0.02% |
| Taha Kass-Hout | Chief Science & Technology Officer | 0.01% |
| James Saccaro | Former Vice President | 0.01% |
| Kevin O’Neill | President & CEO of Pharmaceutical Diagnostics | 0.00% |
| Kenneth Stacherski | Former Chief Global Supply Chain & Service Officer | 0.00% |
| Anne Madden | Independent Director | 0.00% |
| Roland Rott | Former President & CEO of Imaging | 0.00% |
| Catherine Estrampes | Chief Commercial & Growth Officer and Head of Global Markets | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-03 | James Saccaro | Former Vice President | Intent to Sell (Form 144) | -78,348 | $85.92 |
| 2026-09-13 | William Grogan | Chief Financial Officer | Other Acquisition | +75,096 | -- |
| 2026-09-13 | William Grogan | Chief Financial Officer | Other Derivative Acquisition | +31,877 | $64.25 |
| 2026-09-02 | Peter Arduini | Chief Executive Officer | Sale to Issuer | -6,303 | $70.56 |
| 2026-09-02 | George Newcomb | Controller & Chief Accounting Officer | Sale to Issuer | -112 | $70.56 |
| 2026-09-02 | Frank Jimenez | General Counsel | Sale to Issuer | -1,480 | $70.56 |
| 2026-09-02 | Adam Holton | Chief Human Resources Officer | Sale to Issuer | -673 | $70.56 |
| 2026-09-02 | Catherine Estrampes | Chief Commercial & Growth Officer and Head of Global Markets | Sale to Issuer | -508 | $70.56 |
| 2026-09-02 | Philip Rackliffe | President & CEO of Advanced Imaging Solutions (AIS) | Sale to Issuer | -798 | $70.56 |
| 2026-09-02 | Kevin O’Neill | President & CEO of Pharmaceutical Diagnostics | Sale to Issuer | -718 | $70.56 |
| 2026-09-02 | Taha Kass-Hout | Chief Science & Technology Officer | Sale to Issuer | -1,502 | $70.56 |
| 2026-08-31 | Peter Arduini | Chief Executive Officer | Sale to Issuer | -11,515 | $71.23 |
| 2026-08-31 | Frank Jimenez | General Counsel | Sale to Issuer | -3,131 | $71.23 |
| 2026-08-31 | Adam Holton | Chief Human Resources Officer | Sale to Issuer | -659 | $71.23 |
| 2026-08-31 | Jeannette Bankes | President & CEO of Patient Care Solutions | Sale to Issuer | -1,064 | $71.23 |
| 2026-08-31 | Philip Rackliffe | President & CEO of Advanced Imaging Solutions (AIS) | Sale to Issuer | -856 | $71.23 |
| 2026-08-31 | Taha Kass-Hout | Chief Science & Technology Officer | Sale to Issuer | -2,940 | $71.23 |
| 2026-08-14 | Adam Holton | Chief Human Resources Officer | Sale to Issuer | -1,360 | $73.69 |
| 2026-05-21 | Kevin Lobo | Independent Director | Open Market Acquisition | +10,000 | $64.18 |
| 2026-05-14 | Jeannette Bankes | President & CEO of Patient Care Solutions | Sale to Issuer | -5,535 | $62.67 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
GE HealthCare Technologies discussion 0 comments